Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock

MPM BioVentures 2014, L.P., the holding company for Entrada Therapeutics, sold 86,914 shares of common stock in the biotech firm in three transactions during late August 2026. The sales totaled approximately $615,777. The shares traded at a price of $7.05, down 31% for the year, but analysis indicates the company may still be undervalued.

The sales took place on three separate days: August 27, 28, and 31, 2026. On August 27, MPM BioVentures sold 38,922 shares at an average price of $7.20, ranging from $6.88 to $7.37. The following day, August 28, 3,733 shares were sold at a weighted average price of $7.01, trading between $6.95 and $7.24. The final sale on August 31 involved 44,259 shares, averaging $6.99 per share, with prices ranging from $6.76 to $7.16.

These sales were made by various affiliated entities, including MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2018, L.P., MPM BioVentures 2018(B), L.P., and MPM Asset Management Investors BV2018 LLC. After the sales, MPM BioVentures 2014, L.P. indirectly holds 4,231,434 shares of Entrada Therapeutics.

The company's market capitalization stands at $252 million, with a FAIR financial health rating from InvestingPro. Analysts have a strong buy consensus on the stock, with price targets ranging from $11 to $25. Entrada Therapeutics recently secured approval to increase the dose of its ELEVATE-45-201 study for Duchenne Muscular Dystrophy (DMD) from 5 mg/kg to 10 mg/kg, following positive safety and pharmacokinetic data.

The study's multiple ascending dose phase is a crucial step in the biotech company's ongoing research and development efforts.